Tag: rivaroxaban
PAD guideline update from ACC, AHA and others centres multispecialty care
New multisociety clinical practice guidelines for the management of lower extremity peripheral arterial disease (PAD) have been published online in the Journal of the...
VOYAGER PAD subanalysis highlights risks for claudicants undergoing revascularisation
Principal investigator of the VOYAGER PAD trial, Marc Bonaca (University of Colorado Anschutz Medical Campus, Aurora, USA) speaks to Vascular News about the latest data...
Vascular News’ top 10 most popular stories of August 2021
Research presented at the Society for Vascular Surgery’s Vascular Annual Meeting (SVS VAM 2021; 18–21 August, San Diego, USA and online)—including new VOYAGER PAD...
FDA approves expanded PAD indication for Xarelto plus aspirin to include...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the US Food and Drug Administration (FDA) has approved an expanded peripheral arterial...
VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower extremity...
“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev...
Janssen submits application to US FDA for new indication to expand...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the US Food and...
Patients with multiple revascularisations are at higher risk of acute limb...
Symptomatic peripheral arterial disease (PAD) patients undergoing recurrent lower extremity revascularisation have higher rates of ischaemic events, particularly acute limb ischaemia, than those patients...
CX 2020 LIVE: Strong support for relining peripheral arteries and rivaroxaban use for widespread atherosclerosis
In a series of Podium 1st presentations from world-class faculty, CX 2020 LIVE attendees heard the latest data on peripheral arterial disease management and an evaluation of different types of stents, including...
Virtual ACC: Combining aspirin with rivaroxaban reduces risk equally in presence...
In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral endpoints in patients...
Virtual ACC: Aspirin plus rivaroxaban significantly lowers adverse events in PAD...
Treatment with aspirin plus rivaroxaban following lower extremity revascularisation in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk...
Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD...
The National Institute for Health and Care Excellence (NICE) has published the final appraisal determination (FAD) recommending the use of Xarelto (rivaroxaban) by the...
Rivaroxaban recommended by NICE for peripheral and coronary artery disease patients
The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draft final appraisal determination recommending the use of...
PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in...
Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at...
Rivaroxaban gets FDA approval for treatment in CAD or PAD
Rivaroxaban, brand name Xarelto (Janssen), has received approval by the US Food and Drug Administration (FDA) to reduce the risk of major cardiovascular (CV)...
Bayer announces new licensed indication for use of Xarelto in patients...
Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...
COMPASS study of Janssen’s rivaroxaban to end early for efficacy
The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...
Two new real-world studies confirm positive efficacy and safety profile of...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...
